The U.S. House of Representatives passed a bill with bipartisan support that encourages medical cannabis research by easing the federal cannabis research application process.
The U.S. House of Representatives on Tuesday passed a negotiated version of the Medical Marijuana and Cannabidiol Research Expansion Act which would encourage cannabis research by streamlining the federal application process and removing Food and Drug Administration (FDA) barriers.
It marks the second time this year the chamber has approved the measure.
Rep. Earl Blumenauer (D-OR), the bill sponsor, said in a statement that the legislation is “crucial” for researchers and patients to be “able to fully study the health benefits of cannabis.”
“Research is a foundational element for cannabis policy. … . For too long, the federal government has stood in the way of science and progress, creating barriers for researchers obtaining resources and approval to study cannabis. This bipartisan, bicameral legislation is an important first step to changing that.” — Blumenauer in a press release
Republican Rep. Andy Harris (MD), a physician who once conducted National Institute of Health-sponsored research, said he was “pleased” with the bill’s passage “and that scientists will be able to research what medical marijuana can and cannot do.” Although he added that he still “categorically” opposes the recreational use of cannabis.
“While there is evidence to suggest that medical marijuana may be beneficial in the treatment of some diseases like glaucoma and epilepsy, only scientific research will prove the veracity of the many claims regarding efficacy for other diseases,” he said in a statement. “Despite lacking much scientific research, over three dozen states have already legalized medical marijuana, and the American public deserves to know the effect modern marijuana has on the human body.”
The Senate passed a similar bill in 2020 and the bill passed on Tuesday includes provisions from both bills approved by the respective chambers. The measure passed with bipartisan support, including 216 Democrats and 109 Republicans. The Senate is expected to approve the bill.
Rochester, MN: Patients with gastroparesis (partial stomach paralysis) respond favorably to a proprietary spray (Epidiolex) containing plant-derived CBD, according to placebo-controlled data published in the journal Clinical Gastroenterology and Hepatology. Investigators affiliated with the Mayo Clinic in Minnesota compared Epidiolex versus a placebo in 44 patients with gastroparesis. Subjects consumed either CBD or a placebo for a period of…
Boulder, CO: Cancer patients report sustained improvements in pain intensity, cognition, and sleep quality following the use of cannabis-infused edible products, according to observational study data published in the journal Open Exploration. Twenty-five subjects participated in the study. Participants engaged in the ad libitum (as needed) use of state-licensed edible cannabis products for two weeks. “This study is among the first to explore…
Researchers at Australia’s University of Sydney have launched the world’s first-ever study investigating the efficacy of CBD treatments for spinal cord injury-induced chronic pain. Full story after the jump. Researchers at Australia’s University of Sydney are conducting the world’s first medical trial researching the efficacy of CBD for spinal cord injury-induced chronic pain. The study…
This product is not for use by or sale to persons under the age of 18. Consult with a physician before use if you have a serious medical condition or use prescription medications
These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
